Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) EBIT Margin (2021 - 2025)

Kezar Life Sciences' EBIT Margin history spans 5 years, with the latest figure at 4834.11% for Q2 2025.

  • For Q2 2025, EBIT Margin fell 99707.0% year-over-year to 4834.11%; the TTM value through Sep 2025 reached 6310.79%, down 662691.0%, while the annual FY2023 figure was 1591.77%, N/A changed from the prior year.
  • EBIT Margin for Q2 2025 was 4834.11% at Kezar Life Sciences, down from 5080.4% in the prior quarter.
  • Across five years, EBIT Margin topped out at 8869.81% in Q4 2021 and bottomed at 364.67% in Q3 2023.
  • The 5-year median for EBIT Margin is 5964.43% (2022), against an average of 5638.71%.
  • The largest YoY upside for EBIT Margin was 95578bps in 2023 against a maximum downside of -647016bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 8869.81% in 2021, then crashed by -31bps to 6105.48% in 2022, then crashed by -106bps to 364.67% in 2023, then soared by 1620bps to 5543.19% in 2024, then fell by -13bps to 4834.11% in 2025.
  • Per Business Quant, the three most recent readings for KZR's EBIT Margin are 4834.11% (Q2 2025), 5080.4% (Q1 2025), and 5543.19% (Q4 2024).